3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
36
Cholangiocarcinoma
11
Carcinoma, Renal Cell
10
Stomach Neoplasms
5
Liver Neoplasms
5
Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Liver Diseases
2
Kidney Neoplasms
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Breast Neoplasms
2
Advanced Solid Tumor
2
von Hippel-Lindau Disease
1
Urogenital Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Penile Neoplasms
1
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
lenvatinib
×
Clear all
NCT04977453
2026-05-15
Keynote B59
GI Innovation, Inc.
Phase 1/2
Recruiting
317 enrolled